Demystifying Lyme disease.

Save

Few infections have caused as much confusion and controversy as Lyme disease. Since the publication of the first human case series1, how has a disease named after a small town in Connecticut, USA, developed a reputation as a medical enigma?

Lyme disease is caused by infection with Borrelia burgdorferi, a spiral shaped (spirochaete) bacterium, similar microscopically to the causes of Weil’s disease (Leptospirosis) and syphilis (Treponema pallidum)2. B.burgdorferi is transmitted by hard-bodied ticks, small arachnids which are ubiquitous in rural and suburban environments, and Lyme borreliosis is hence the commonest vector-borne disease in the UK and Europe3,4.

B.burgdorferi is primarily spread by Ixodes ricinus, a tick which is widely distributed in woodlands, marshlands and grassy fields throughout the UK5. They feed on small and large mammals, including squirrels, hares and other rodents, cattle and deer6. Ixodes ticks are small, typically the size of a sesame seed (3-5mm), but once engorged with blood can reach the size of an oat seed (10mm)7(Figure 1).

Most human infections (c.85%) occur in spring and summer, when ticks are in the nymphal stage of development2.

As cases of Lyme disease are not notifiable in the UK, accurately estimating the burden on the population is difficult. Data on laboratory-confirmed cases held by the UK Health Security Agency (UKHSA)3 can be combined with retrospective reviews of GP records8, although both approaches have inherent epidemiological limitations, including biases of ascertainment and reporting. Cases of Lyme disease have been reported from every region of the UK, with the highest numbers being consistently from Southern England and from Scotland3,8.

In 2024 there were 1,581 laboratory-confirmed cases in England, mostly in people aged 35 to 64 years old (54%), with similar numbers of males and females affected3.

There are some common misconceptions about how Lyme disease should be diagnosed.

Firstly, a reported tick bite is not required to rule in a possible diagnosis. Ticks are very small and have anaesthetising saliva. Only 40% of confirmed cases recall having had a tick bite2 and, in individuals presenting with compatible symptoms, seeking a history of potential exposure is therefore more important.

This should include asking about hiking and other outdoor activities, particularly in the spring and summer months. The extent of clothing coverage (long sleeves and trousers) can help to protect against, but not prevent, picking up ticks.

Secondly, a blood test is not needed to diagnose Lyme disease. Up to 80% of cases will develop a characteristic expanding ‘bulls-eye’ rash, known as erythema migrans (EM)9(Figure 2). A high index of clinical suspicion is also required, however, as the EM rash can be harder to distinguish in patients with dark skin, and can also disseminate or present atypically9.

EM typically arises 7-14 days after exposure9. If EM is present and there is a history of possible exposure, a clinical diagnosis should be made and antibiotics offered promptly to resolve symptoms and prevent complications10(Figure 3). First line treatment for adults and children over 12 years old is a 21-day course of oral doxycycline; in pregnancy amoxicillin can be used11.

Early treatment is important as complications of Lyme disease, potentially affecting nerves, skin, joints and heart, can be highly debilitating10. Cardiac and neurological involvement, e.g. heart block or meningitis, can be particularly serious and warrant referral to an infection specialist for assessment and treatment10. Central nervous system symptoms should be investigated with lumbar puncture and imaging; antibiotic treatment should be with an intravenous agent capable of crossing the blood-brain barrier (e.g. ceftriaxone)10.

In England, an average of 81 cases per year of laboratoryconfirmed acute neurological Lyme disease were reported by the UKHSA between 2019 and 20233.

If EM is not present but there are other ongoing compatible symptoms, a credible exposure, and no clear alternative diagnosis, then serological testing should be considered10. The National Institute of Health and Care Excellence (NICE) recommends two-tier serological investigations10 that optimise specificity whilst maintaining high sensitivity for Lyme disease (Figure 3). Initial screening should be with an enzyme-linked immunoassay (EIA); any patients with a positive or equivocal IgM or IgG on EIA should be discussed with a specialist and the next step will generally be to request a confirmatory immunoblot10.

Two-tiered serology is preferred because the initial bacteraemia in Lyme disease is short-lived, meaning that direct detection with polymerase chain reaction (PCR) tests lack sensitivity and result in a high proportion of false negative results12. Cellular tests which measure invitro leukocyte response to pathogen-specific antigens are available from various private laboratories offering diagnostic tests for Lyme disease. These have been shown in case-control studies to have lower specificity compared to two-tiered serology, meaning higher rates of false-positive results13, and are hence not currently recommended for use in the NHS.

Serological tests also have their limitations. Cross-reactivity with other infections and inflammatory conditions can cause false-positive results, while testing too early (i.e. within 4-6 weeks from symptom onset) can return a false-negative result10. Due to these limitations, NICE recommends repeat testing in cases where early disease is suspected10.

Immunoblot tests for borrelia are not universally available in clinical laboratories, and in the UK these are provided by the UKHSA’s Rare and Imported Pathogens Laboratory (RIPL)14. If the immunoblot test is negative (regardless of the EIA result) and symptoms persist, a referral to a specialist to consider whether further tests for Lyme disease may be needed, e.g. synovial fluid aspirate, biopsy or lumbar puncture for cerebral spinal fluid analysis, alongside a holistic assessment to identify possible alternative diagnoses10. The specialist chosen should be appropriate to a patient’s history and ongoing symptoms, e.g. an adult or paediatric infection specialist, rheumatologist or neurologist.

Post Treatment Lyme Disease Syndrome (PTLDS) refers to the presence of persistent symptoms, e.g. fatigue, pain and cognitive difficulties, persisting beyond 6 months after completing effective antibiotic treatment2. These are symptoms that can also occur after other infectious diseases and should be treated with great care and sensitivity as they can significantly affect quality of life. It is important to ensure that alternative diagnoses have not been overlooked, including malignancy, autoimmune/autoinflammatory disease, demyelinating processes, and mental health problems2.

There is currently no good quality evidence in patients who have been diagnosed with PTLDS of either persistent infection or of benefit from prolonged or multiple courses of antibiotics2.

Key learning points:

A history of a tick bite is not required to rule in a possible diagnosis of Lyme disease.

Most diagnoses of Lyme disease can be made without using blood tests. A clinical diagnosis is sufficient if erythema migrans and a history of possible exposure are both present, and antibiotics should be offered as soon as possible to prevent complications.

In the absence of erythema migrans, serological investigations should be pursued if the patient has ongoing symptoms and there is ongoing clinical suspicion about an underlying diagnosis of Lyme disease.

Related articles

PubMed

Urbanicity and Lyme Disease: 20 Year Trends in Incidence and Case Burden in the United States.

ABSTRACT Incidence of Lyme disease (LD) has increased over the last few decades in the United States (US). We examined trends in LD incidence and case burden in high‐incidence jurisdictions in the US from 2000 to 2021 by urbanicity. County‐level counts of confirmed LD cases from 2000 to 2021 were obtained from national surveillance data. Incidence rates were calculated using census population projections. Urbanicity was categorized using Rural–Urban Continuum Codes (RUCC). Mixed effects models...

PubMed

Molecular evidence of spotted fever group Rickettsia and Lyme disease- and relapsing fever-associated Borrelia, and the absence of scrub typhus-associated Orientia in ixodid ticks from contrasting habitats in Peninsular Malaysia.

Tick-borne pathogens are emerging across Southeast Asia, but their diversity and ecological drivers in Malaysia remain poorly understood. We screened 539 ixodid ticks collected from natural forests, marginal habitats, and oil palm plantations in Peninsular Malaysia for Rickettsia spp., Borrelia spp., and Orientia tsutsugamushi using PCR and phylogenetic analyses. Overall, 10.61% (7/66) of tick pools tested positive for bacterial pathogens. Rickettsia was detected in 4.55% (3/66) of pools from De...